IL290595A - Compositions and methods for modulating splicing and protein expression - Google Patents

Compositions and methods for modulating splicing and protein expression

Info

Publication number
IL290595A
IL290595A IL290595A IL29059522A IL290595A IL 290595 A IL290595 A IL 290595A IL 290595 A IL290595 A IL 290595A IL 29059522 A IL29059522 A IL 29059522A IL 290595 A IL290595 A IL 290595A
Authority
IL
Israel
Prior art keywords
expression
compositions
methods
protein fusion
modulating protein
Prior art date
Application number
IL290595A
Other languages
English (en)
Hebrew (he)
Original Assignee
Stoke Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stoke Therapeutics Inc filed Critical Stoke Therapeutics Inc
Publication of IL290595A publication Critical patent/IL290595A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL290595A 2019-08-19 2022-02-13 Compositions and methods for modulating splicing and protein expression IL290595A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962888887P 2019-08-19 2019-08-19
US202063049262P 2020-07-08 2020-07-08
PCT/US2020/047081 WO2021034985A1 (en) 2019-08-19 2020-08-19 Compositions and methods for modulating splicing and protein expression

Publications (1)

Publication Number Publication Date
IL290595A true IL290595A (en) 2022-04-01

Family

ID=74659533

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290595A IL290595A (en) 2019-08-19 2022-02-13 Compositions and methods for modulating splicing and protein expression

Country Status (11)

Country Link
US (1) US20220290142A1 (cg-RX-API-DMAC10.html)
EP (1) EP4017979A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022544702A (cg-RX-API-DMAC10.html)
KR (1) KR20220104677A (cg-RX-API-DMAC10.html)
CN (1) CN114746550A (cg-RX-API-DMAC10.html)
AU (1) AU2020334067A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022002905A2 (cg-RX-API-DMAC10.html)
CA (1) CA3147970A1 (cg-RX-API-DMAC10.html)
IL (1) IL290595A (cg-RX-API-DMAC10.html)
MX (1) MX2022002198A (cg-RX-API-DMAC10.html)
WO (1) WO2021034985A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12559747B2 (en) * 2019-05-27 2026-02-24 Vision Pharma Pty Ltd Retinitis pigmentosa treatment
KR20220054401A (ko) * 2019-09-03 2022-05-02 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물
US20230174984A1 (en) * 2020-05-11 2023-06-08 The Florey Indtitute of Neuroscience and Mental Health Compositions and methods for treating disorders associated with loss-of-function mutations in syngap1
CN117980479A (zh) * 2021-06-21 2024-05-03 斯托克制药公司 用于治疗基于无义介导的rna衰变的病状和疾病的反义寡聚体
EP4373845A4 (en) * 2021-07-23 2025-06-25 The Children's Medical Center Corporation Zinc finger ccch-type containing 14 (zc3h14) mutants and methods of use
CA3252931A1 (en) * 2022-02-24 2023-08-31 Quiver Holdings Inc. THERAPEUTIC AGENTS FOR HAPLOINS SUFFICIENCY OF SYNGAP
EP4504951A4 (en) * 2022-04-05 2026-07-15 Univ Johns Hopkins METHODS AND MATERIALS FOR TREATING NEURODEVELOPMENTAL DISORDERS ASSOCIATED WITH SYNGAP1
WO2023212625A1 (en) * 2022-04-28 2023-11-02 AcuraStem Incorporated Syf2 antisense oligonucleotides
US20250313832A1 (en) * 2022-05-13 2025-10-09 The Trustees Of The University Of Pennsylvania Compositions for treating syngap-1 related neurodevelopmental disorders
JP2025522625A (ja) * 2022-06-28 2025-07-15 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ オリゴヌクレオチド
WO2025090628A1 (en) * 2023-10-23 2025-05-01 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising small nuclear rna (snrna) for treating genetic epilepsies
WO2025111249A2 (en) * 2023-11-20 2025-05-30 Dana-Farber Cancer Institute, Inc. Methods, kits and systems for determining sarcomatoid differentiation of renal cell carcinoma and methods for treating based on the same
GB202401412D0 (en) * 2024-02-02 2024-03-20 Harness Therapeutics Ltd Functional nucleic acid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009064920A2 (en) * 2007-11-13 2009-05-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
JP2012507989A (ja) * 2008-11-07 2012-04-05 センター ホスピタライヤー ユニヴェルシテール サント−ジュスティーヌ Syngap1機能不全ならびに精神遅滞の診断および治療用途でのその使用
CN107109411B (zh) * 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
CN108603230A (zh) * 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
CN116059236A (zh) * 2015-12-14 2023-05-05 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
CA3005131A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of tuberous sclerosis complex
JP7049247B2 (ja) * 2015-12-14 2022-04-06 コールド スプリング ハーバー ラボラトリー 腎臓病の処置のための組成物と方法
WO2017106283A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of liver diseases
CA3005247A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of polycystic kidney disease
JP7036723B2 (ja) * 2015-12-14 2022-03-15 コールド スプリング ハーバー ラボラトリー 眼疾患の処置のための組成物および方法
JP2019535789A (ja) * 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
KR20260009385A (ko) * 2017-08-25 2026-01-19 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
LT3700570T (lt) * 2017-10-23 2025-04-10 Stoke Therapeutics, Inc. Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui

Also Published As

Publication number Publication date
BR112022002905A2 (pt) 2022-07-12
CA3147970A1 (en) 2021-02-25
KR20220104677A (ko) 2022-07-26
MX2022002198A (es) 2022-05-24
US20220290142A1 (en) 2022-09-15
WO2021034985A1 (en) 2021-02-25
EP4017979A4 (en) 2024-03-27
CN114746550A (zh) 2022-07-12
JP2026108794A (ja) 2026-06-30
AU2020334067A1 (en) 2022-03-17
EP4017979A1 (en) 2022-06-29
JP2022544702A (ja) 2022-10-20

Similar Documents

Publication Publication Date Title
EP3920918A4 (en) METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
IL287398A (en) Methods and preparations for modulating composition and translation
ZA202004932B (en) Methods and compositions for modulating splicing
EP3920915A4 (en) METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
EP3920919A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920916A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920920A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3921311A4 (en) METHODS AND COMPOSITIONS FOR SPLICING MODULATION
EP3938352A4 (en) METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920910A4 (en) METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
EP3688187A4 (en) PROCEDURES AND COMPOSITIONS FOR SCREENING AND IDENTIFYING SPICE MODULATORS
EP3688012A4 (en) COMPOUNDS AND METHODS FOR MODULATING PROTEIN DEGRADATION
EP4017979A4 (en) COMPOSITIONS AND METHODS FOR MODULATING SPLICING AND PROTEIN EXPRESSION
IL286681B1 (en) Compounds and methods for modulating UBE3A-ATS
EP3870173A4 (en) WDR5 INHIBITORS AND MODULATORS
EP3256163A4 (en) Methods and compositions for modulating lilr proteins
IL307625A (en) Compounds and methods for modulating pnpla3 expression
EP3860618A4 (en) METHODS AND COMPOSITIONS FOR MODULATING TAU PROTEINS
HK40076949A (en) Compositions and methods for modulating splicing and protein expression
EP4045043A4 (en) COMPOUNDS AND METHODS FOR MODULATING IMMUNE PROTEINS
HK40070060A (en) Methods and compositions for modulating splicing and translation
HK40029842A (en) Methods and compositions for modulating splicing
HK40082816A (en) Compositions and methods for modulating factor viii function
HK40060585A (en) Compositions and methods for modulating factor viii function